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2051REPLY: The Strain, the Valve, andthe LVOT ObstructionWe were interested by Dr. Ntelios and colleagues’
response to our paper (1). We found that in patients
with obstructive hypertrophic cardiomyopathy (HCM)
there is left ventricular (LV) ﬂow that impacts the
posterior surface of the mitral leaﬂet tips, causing
the initial systolic anterior motion (SAM) (1,2). Early
systolic velocity vector ﬂow overlaps the leaﬂets by
w10 mm; this does not occur in normal and rarely in
nonobstructed patients. At high angles of attack of
the ﬂow onto the leaﬂets, drag, the pushing force of
ﬂow, is the dominant hydrodynamic force. An addi-
tional important contributor to drag is abnormally
elongated mitral leaﬂets. In w60% of patients, early
SAM is caused by ejection ﬂow sweeping around the
bulging septum, overlapping with, and striking the
mitral leaﬂet surfaces posteriorly. Otherwise, SAM is
initiated by the anteriorly directed isovolumic vortex
before ejection begins. After mitral-septal contact,
the pressure gradient pushes the leaﬂet further into
the septum (2).
Dr. Ntelios and colleagues propose that increased
basal circumferential strain in obstructive HCM
might narrow the outﬂow tract and contribute
to SAM etiology. However, SAM and mitral-septal
contact occur very early in systole, well before the
effects of peak strain. With high resting gradients,
SAM began 75 to 95 ms after the R-wave, and
mitral-septal contact occurred at 168 to 183 ms (3).
In HCM, peak basal circumferential strain occurs at
391 ms (4). Thus, the key events that establish LV
outﬂow tract obstruction are over well before peak
strain. Ventricular mechanics modulate SAM and
gradient through global contractility, and very early
ejection ﬂow acceleration, which impacts the mitral
valve and pushes it into the septum with a force
that is proportional to the square of the ﬂow
velocity (2).
SAM, mitral-septal contact, and signiﬁcant gradi-
ents have been observed in Takostubo syndrome. We
hypothesize that SAM does not occur because the
base becomes hypercontractile, but rather that SAM
originates from altered left ventricular geometry.
After mid and apical LV dilation, the remaining
normal septum bulges at the base. It redirects the
ﬂow coursing down the septum posteriorly and
laterally, behind the mitral valve, causing SAM. The
geometry that sets up this abnormally directed ﬂow is
shown by Hurst et al. in Figure 1G (5). Support of this
hypothesis would require vector ﬂow map imaging
in these patients. The causes of SAM after mitral
repair have been well elucidated: the anterior leaﬂetprotrudes into the ejection ﬂow stream, where it
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Getting Guidelines
CorrectTheir Evidence-Based Recommendations for
Use of Nonstatins Added to Statins and the
Need for Follow-Up Lipid TestingAs part of the writing group for the 2013 American
College of Cardiology/American Heart Association
Cholesterol Guidelines for adults, we wish to point
out that the recent paper by Maddox et al. (1) contains
some important inaccuracies about the cholesterol
guidelines that should be corrected.
First, they incorrectly state what the cholesterol
guideline wrote about the use of nonstatins (2).
While it is true that the cholesterol guidelines
do not make a Class I recommendation of non-
statin therapies for routine risk reduction of
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2052atherosclerotic cardiovascular disease (ASCVD),
there is an entire section on nonstatins, including
the following paragraph on page 2913 in Section
6.3.2 of the guideline.
Clinicians treating high-risk patients who have a
less-than-anticipated response to statins, who are
unable to tolerate a less-than-recommended in-
tensity of a statin, or who are completely statin
intolerant, may consider the addition of a nonstatin
cholesterol-lowering therapy. High-risk individuals
include those with ASCVD, those with LDL-C $190
mg/dl, and those with diabetes 40–75 years of age. In
this situation, this guideline recommends clinicians
preferentially prescribe drugs that have been shown
in RCTs to provide ASCVD risk-reduction beneﬁts
that outweigh the potential for adverse effects and
drug-drug interactions and consider patient prefer-
ences (2).
This not an inconsequential point. In recent
randomized controlled trials (RCTs), niacin and
ezetemibe, when added to intensive statin therapy,
both lowered low-density lipoprotein cholesterol
(LDL-C), but the addition of niacin did not result in
improved outcomes and was associated with safety
issues (3,4). This is contrasted with a recently
reported RCT in a high-risk acute coronary syn-
drome population with 1 high-risk feature, where
addition of ezetemibe to a moderate-intensity statin
was shown to be both safe and incrementally
effective (5).
Second, they incorrectly state what the guide-
lines say about follow-up therapy. Although the
guidelines no longer endorse arbitrary LDL-C goals,
we are uncertain how the authors could infer
that the guidelines require little or no follow-up
therapy.
Figure 5, entitled “Monitoring Therapeutic Res-
ponse and Adherence,” and associated text on pages
2912 to 2913 indicate that the guidelines endorse
follow-up lipids, especially LDL-C. Follow-up lipids
are needed to not only determine attainment of the
therapeutic response to the appropriate intensity of
statin, but also to monitor adherence to statin and
lifestyle therapy.
Both of these errors are serious threats to the
appropriate use of this evidence-based guideline.
We respectfully request that Maddox et al. submit
an erratum to the journal to correct these inac-
curate statements regarding the 2013 American
College of Cardiology/American Heart Association
guideline on the treatment of blood cholesterol to
reduce the risk of atherosclerotic cardiovascular
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REPLY: Getting Guidelines CorrectTheir Evidence-Based Recommendations for Use of
Nonstatins Added to Statins and the Need for Follow-Up
Lipid TestingWe appreciate the comments made by Dr. Stone
and colleagues regarding our paper discussing impli-
cations of the 2013 American College of Cardiology/
American Heart Association cholesterol guidelines (1).
As Dr. Stone and colleagues correctly point out, the
guidelines did not forbid nonstatin lipid-lowering
therapies, but rather suggested that clinicians “may
consider the addition of a nonstatin cholesterol-
lowering therapy” (1). At the time of the guideline
release and our paper publication, there were no
randomized, controlled trials (RCTs) that had dem-
onstrated cardiovascular (CV) event reduction be-
neﬁt with nonstatin lipid-lowering medications.
Thus, our statements indicating that these nonstatin
